Flagship Harbor Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.69M | Sell |
70,067
-1,559
| -2% | -$40.8K | 0.06% | 257 |
|
|
2026
Q1 | $2.01M | Sell |
71,626
-2,612
| -4% | -$69.5K | 0.09% | 197 |
|
|
2025
Q4 | $1.85M | Sell |
74,238
-3,108
| -4% | -$78.4K | 0.09% | 200 |
|
|
2025
Q3 | $1.97M | Buy |
77,346
+3,278
| +4% | +$80.9K | 0.09% | 204 |
|
|
2025
Q2 | $1.8M | Buy |
74,068
+7,668
| +12% | +$179K | 0.09% | 213 |
|
|
2025
Q1 | $1.68M | Buy |
66,400
+1,585
| +2% | +$41.5K | 0.09% | 208 |
|
|
2024
Q4 | $1.72M | Buy |
64,815
+1,000
| +2% | +$27.1K | 0.09% | 198 |
|
|
2024
Q3 | $1.85M | Sell |
63,815
-947
| -1% | -$27.6K | 0.1% | 189 |
|
|
2024
Q2 | $1.81M | Sell |
64,762
-1,901
| -3% | -$52.3K | 0.11% | 183 |
|
|
2024
Q1 | $1.85M | Buy |
66,663
+9,889
| +17% | +$274K | 0.12% | 169 |
|
|
2023
Q4 | $1.63M | Buy |
56,774
+5,454
| +11% | +$165K | 0.12% | 167 |
|
|
2023
Q3 | $1.7M | Sell |
51,320
-106
| -0.2% | -$3.75K | 0.14% | 143 |
|
|
2023
Q2 | $1.89M | Sell |
51,426
-10,514
| -17% | -$409K | 0.16% | 139 |
|
|
2023
Q1 | $2.53M | Buy |
61,940
+287
| +0.5% | +$12.4K | 0.24% | 108 |
|
|
2022
Q4 | $3.16M | Buy |
61,653
+7,253
| +13% | +$348K | 0.32% | 81 |
|
|
2022
Q3 | $2.38M | Buy |
54,400
+2,039
| +4% | +$99.1K | 0.28% | 93 |
|
|
2022
Q2 | $2.75M | Buy |
52,361
+7
| +0% | +$357 | 0.31% | 79 |
|
|
2022
Q1 | $2.71M | Buy |
52,354
+232
| +0.4% | +$12K | 0.26% | 96 |
|
|
2021
Q4 | $3.08M | Buy |
52,122
+2,244
| +4% | +$111K | 0.29% | 76 |
|
|
2021
Q3 | $1.95M | Hold |
49,878
| – | – | 0.21% | 111 |
|
|
2021
Q2 | $1.95M | Sell |
49,878
-2,137
| -4% | -$83.1K | 0.21% | 111 |
|
|
2021
Q1 | $1.88M | Sell |
52,015
-2,369
| -4% | -$84.1K | 0.21% | 108 |
|
|
2020
Q4 | $2M | Sell |
54,384
-2,373
| -4% | -$87K | 0.25% | 88 |
|
|
2020
Q3 | $1.98M | Sell |
56,757
-3,892
| -6% | -$136K | 0.27% | 78 |
|
|
2020
Q2 | $1.88M | Buy |
60,649
+16,116
| +36% | +$548K | 0.28% | 78 |
|
|
2020
Q1 | $1.38M | Sell |
44,533
-2,553
| -5% | -$87K | 0.28% | 76 |
|
|
2019
Q4 | $1.75M | Buy |
47,086
+2,431
| +5% | +$86.6K | 0.31% | 72 |
|
|
2019
Q3 | $1.52M | Buy |
44,655
+3,977
| +10% | +$145K | 0.3% | 72 |
|
|
2019
Q2 | $1.67M | Buy |
40,678
+3,439
| +9% | +$137K | 0.35% | 67 |
|
|
2019
Q1 | $1.5M | Sell |
37,239
-7,406
| -17% | -$297K | 0.31% | 78 |
|
|
2018
Q4 | $1.85M | Sell |
44,645
-11,069
| -20% | -$459K | 0.45% | 50 |
|
|
2018
Q3 | $2.34M | Sell |
55,714
-6,283
| -10% | -$242K | 0.43% | 48 |
|
|
2018
Q2 | $2.13M | Buy |
61,997
+6,199
| +11% | +$212K | 0.43% | 51 |
|
|
2018
Q1 | $1.86M | Buy |
55,798
+7,492
| +16% | +$258K | 0.55% | 48 |
|
|
2017
Q4 | $1.67M | Buy |
48,306
+4,619
| +11% | +$157K | 0.48% | 54 |
|
|
2017
Q3 | $1.5M | Buy |
43,687
+306
| +0.7% | +$9.84K | 0.49% | 56 |
|
|
2017
Q2 | $1.37M | Buy |
43,381
+4,332
| +11% | +$137K | 0.48% | 59 |
|
|
2017
Q1 | $1.26M | Buy |
39,049
+3,388
| +10% | +$107K | 0.48% | 61 |
|
|
2016
Q4 | $1.07M | Buy |
+35,661
| New | +$1.09M | 0.46% | 62 |
|
Other funds holding PFE
Flagship Harbor Advisors's PFE Position: Q2 2026 in Review
Flagship Harbor Advisors reduced its Pfizer (PFE) stake by 2.2% in Q2 2026, selling an estimated $40.8K and leaving 70,067 shares worth $1.69M. The position accounts for 0.06% of the portfolio, ranked #257.
Flagship Harbor Advisors first reported a position in PFE in Q4 2016 and has held it in 39 quarters since. The position peaked at $3.16M in Q4 2022. 1,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Flagship Harbor Advisors held 70,067 shares of Pfizer worth $1.69M as of Q2 2026.
- Flagship Harbor Advisors sold 1,559 Pfizer shares in Q2 2026, an estimated $40.8K.
- Pfizer made up 0.06% of Flagship Harbor Advisors's portfolio in Q2 2026, its #257 holding.
- Flagship Harbor Advisors first reported a position in Pfizer in Q4 2016 and has held it in 39 quarters since.
- Flagship Harbor Advisors's Pfizer position peaked at $3.16M in Q4 2022.
- 1,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Flagship Harbor Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.